Mylan Urges Court To Nix AstraZeneca's Diabetes Drug Patent
A Mylan Pharmaceuticals subsidiary has alleged that intellectual property protections underpinning AstraZeneca's billion dollar diabetes drug Farxiga should be invalidated, as the generics company gears up to market its own version...To view the full article, register now.
Already a subscriber? Click here to view full article